Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,758 shares of the stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $32.14, for a total transaction of $345,762.12. Following the completion of the transaction, the chief financial officer owned 8,638 shares of the company’s stock, valued at $277,625.32. This represents a 55.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adam Scott Levy also recently made the following trade(s):

• On Tuesday, November 11th, Adam Scott Levy sold 119,524 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $44.88, for a total transaction of $5,364,237.12.

Mineralys Therapeutics Trading Down 6.1%

Shares of MLYS opened at $31.38 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $47.65. The firm has a market capitalization of $2.48 billion, a P/E ratio of -10.64 and a beta of 0.49. The firm’s 50-day moving average is $38.51 and its two-hundred day moving average is $30.91.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. Analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Stifel Nicolaus raised their price target on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company raised their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, HC Wainwright upped their price target on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Mineralys Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Institutional Trading of Mineralys Therapeutics

A number of large investors have recently made changes to their positions in MLYS. Hennion & Walsh Asset Management Inc. raised its stake in Mineralys Therapeutics by 31.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 69,362 shares of the company’s stock valued at $2,517,000 after purchasing an additional 16,514 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Mineralys Therapeutics by 130.7% during the fourth quarter. SG Americas Securities LLC now owns 230,795 shares of the company’s stock worth $8,376,000 after buying an additional 130,758 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of Mineralys Therapeutics during the third quarter worth about $2,873,000. Armistice Capital LLC raised its position in shares of Mineralys Therapeutics by 185.2% in the third quarter. Armistice Capital LLC now owns 507,650 shares of the company’s stock valued at $19,250,000 after buying an additional 329,650 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Mineralys Therapeutics during the third quarter valued at approximately $714,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.